PARADIGM-HF
PARADIGM-HF is the largest study to date in heart failure patients. 1
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
PARADIGM-HF is the largest study to date in heart failure patients. 1
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...
Sacubitril/valsartan, a first-in-class ARNI, delivers simultaneous inhibition of neprilysin and blockade of the AT1 receptor. Sacubitril/valsartan is a sodium salt complex comprising sacubitril (AHU377), a prodrug, which is further metabolized to the...
ENTRESTO ® is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. ENTRESTO is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic...
Together for Better In the fight against heart failure condition, we work our hardest every day to develop innovative and effective medication to sustain a better life, keeping the patient in mind. We are aware that the result of...